Trial Profile
Phase Ib/II Study of Autologous Dendritic Cell Therapy Delivered Intratumorally After Cryoablation in Combination With Pembrolizumab for Patients With Metastatic or Unresectable Melanoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Jan 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Dendritic cells
- Indications Malignant melanoma
- Focus Therapeutic Use
- 25 Oct 2022 Planned End Date changed from 31 Oct 2022 to 31 Oct 2024.
- 01 Dec 2021 Status changed from suspended to active, no longer recruiting.
- 18 Nov 2020 Status changed from recruiting to suspended.